Literature DB >> 8760929

A low-fibronectin-binding mutant of Staphylococcus aureus 879R4S has Tn918 inserted into its single fnb gene.

C Greene1, P E Vaudaux, P Francois, R A Proctor, D McDevitt, T J Foster.   

Abstract

A low-fibronectin-binding mutant of Staphylococcus aureus strain 879R4SSp generated by transposon Tn918 mutagenesis is attenuated in a rat endocarditis model (J.M. Kuypers & R.A. Procter, 1989, Infect Immun 57, 2306-2312). PCR and Southern hybridization analysis with primers and probes, respectively, for the fnbA and fnbB genes of strains 8325-4 showed that strain 879R4SSp possesses a single fnb gene which is homologous to fnbA. This was confirmed by sequencing 41 bp of 5' non-coding and 237 bp of 5' coding DNA, which showed 97% base identity to fnbA. Southern hybridization and sequencing showed that Tn918 was inserted 41 bp 5' to fnbA in the mutant 879R4SSp/1536, between the promoter and initiation codon. Reduced adherence of the mutant to surface-bound fibronectin correlated with lower expression of a 180 kDa wall-associated fibronectin-binding protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760929     DOI: 10.1099/13500872-142-8-2153

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  8 in total

Review 1.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

2.  Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis.

Authors:  Y A Que; P François; J A Haefliger; J M Entenza; P Vaudaux; P Moreillon
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin.

Authors:  C Bisognano; P E Vaudaux; D P Lew; E Y Ng; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin.

Authors:  C Bisognano; P Vaudaux; P Rohner; D P Lew; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

5.  Variance in fibronectin binding and fnb locus polymorphisms in Staphylococcus aureus: identification of antigenic variation in a fibronectin binding protein adhesin of the epidemic CMRSA-1 strain of methicillin-resistant S. aureus.

Authors:  K Rice; M Huesca; D Vaz; M J McGavin
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

6.  Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phenotypes.

Authors:  Pierre Vaudaux; Patrice Francois; Carmelo Bisognano; William L Kelley; Daniel P Lew; Jacques Schrenzel; Richard A Proctor; Peter J McNamara; G Peters; Christof Von Eiff
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Endovascular infections caused by methicillin-resistant Staphylococcus aureus are linked to clonal complex-specific alterations in binding and invasion domains of fibronectin-binding protein A as well as the occurrence of fnbB.

Authors:  Yan Q Xiong; Batu K Sharma-Kuinkel; Nadia N Casillas-Ituarte; Vance G Fowler; Thomas Rude; Alex C DiBartola; Roberto D Lins; Wessam Abdel-Hady; Steven K Lower; Arnold S Bayer
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

8.  Introduction of the mec element (methicillin resistance) into Staphylococcus aureus alters in vitro functional activities of fibrinogen and fibronectin adhesins.

Authors:  P E Vaudaux; V Monzillo; P Francois; D P Lew; T J Foster; B Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.